JPRN-UMIN000049304招募中Unknown
Randomized Phase II selection trial of Stereotactic Prostate Irradiation with Dose Escalated Region - SPIDER II trial
Kitasato univeristy0 个研究点目标入组 60 人开始时间: 2022年11月1日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •(1) Patients with active multiple cancers (excluding metachronous multiple cancers with an expected prognosis of 5 years or longer and synchronous multiple cancers with an expected prognosis of 5 years or longer with treatment) (2) Patients with uncontrolled diabetes (HbAlc 8.0% or more as a guideline) (3) Patients judged by the attending physician to have serious complications such as connective tissue disease, heart disease, respiratory disease, liver disease, etc. (4) Patients who are complicated by psychosis or psychiatric symptoms and are judged to be difficult to participate in the study (5) Patients who have previously received radiotherapy to the pelvis (6) Patients who have undergone surgical therapy for the prostate (transurethral prostatectomy, subcapsular prostatectomy, orchiectomy, etc.) or HIFU (high-intensity focused ultrasound) (7) Patients who received chemotherapy other than androgen deprivation therapy for prostate cancer (8) Patients with inflammatory bowel disease such as Crohn's disease or ulcerative colitis (9) Patients who are judged to be unable to comply with dose restrictions due to the proximity of risk organs such as the urethra and large intestine to the PTV estimated by diagnostic imaging. (10) Patients who are judged inappropriate for clinical trial participation by the attending physician
研究者
相似试验
进行中（未招募）
1 期
A phase 2 trial for patients with metastatic prostate cancer to study treatment with nivolumab and ipilimumab with or without radiotherapymetastatic castration-resistant prostate cancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036920Term: Prostate cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003461-34-DKDepartment of Oncology, Herlev & Gentofte Hospital90
进行中（未招募）
1 期
Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II trialCTIS2024-513207-13-00Institut De Cancerologie De L Ouest96
已完成
3 期
A randomized controlled trial of stereotactic body radiation therapy (SBRT) with radiofrequency ablation (RFA) for small hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000002488Department of Gastroenterology, National Hospital Organization, Kyoto Medical Center288
终止
2 期
Study to assess the neurological and cognitive effects of using Hypofractionated Stereotactic Radiotherapy used to treat multiple (3-10) brain metastases.eurocognitive impairmentNeurocognitive impairmentCancer - Any cancerCancer - BrainACTRN12615001202550Icon Cancer Foundation30
招募中
3 期
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10)NL-OMON52850ondon Health Sciences Center- Lawson Health Research Institute20